CBA 抗击新型冠状病毒知识系列讲座-2 抗击新型冠状病毒创新药物的研发 

演讲嘉宾:Dr. Patrick Lu, Sirnaomics Inc.                                     Dr. Shoubai Chao, CanSino Biologics Inc.

点评嘉宾:Dr. Hang Lu                               

庚子伊始,正值中国传统佳节春节来临之际,一场突如其来的“2019 新型冠状病毒”疫情向 我们无情袭来,不断蔓延的疫情更是牵动了无数 CBA 成员和朋友们的心,许多我们熟知 CBA 的骨干企业及个人,已经直接或间接地投入到了这场没有硝烟的战斗中! 抗疫情,CBA 在行动!作为 CBA 抗疫行动的一部分,CBA Biomarker Study Group 和 CBA Clinical and Regulatory Affair Study group 决定联合举办抗击新型冠状病毒肺炎知识系列讲座(CBA Anti-COVID-19 Webinar Series);这个系列讲座将就大家关注的新型冠状病毒的科学知识,流行病防控战略和机制,抗病毒药物制备和临床试验,病毒检测方法和应用, 特殊时期 FDA 的药政法规,防控工作的中长期规划等一系列问题,邀请本地的专家、学者、政府官员、企业家、工程技术人员来分享他们的真知灼见,并回答大家的问题。这个讲座将对 CBA 及社会公众开放,听众可用 Zoom 来加入。本讲座由商图信息(BIOMAP)负责中国国内推广。 御风雪呼唤抱薪者,抗疫情更需你我他。欢迎大家积极参加,并把您的宝贵意见反馈给我们。让我们携起手来,风雨同舟,共克时艰,将点滴爱心汇成江河,呼唤春风化雨,散尽阴霾,共盼灿烂阳光的到来!  

  时间:  2 月 26 日 周三晚上 8:30-9:30(美东时间); 2月27日周四上午9:30-10:30 (中国时间)。

讲座形式:线上讲座(webinar)

Webinar 链接的详细信息如下:

Register in advance for this meeting is required: 请事前注册:
https://zoom.us/meeting/register/tZAkfuyhqj8rMVV-GvB1aKLE_WEUV3SFUA

After registering, you will receive a confirmation email containing information about joining the meeting. 注册后,你将收到确认的电子邮件,还会告诉你参会的具体信息。

讲座内容:

报告1:RNAi技术是开发治疗新冠肺炎创新药物的有效方法

报告人:陆阳 博士

A person wearing a suit and tieDescription automatically generated

Patrick Lu, PhD, CEO and Chairman of Sirnaomics Inc., the 2nd President of CBA. Dr. Lu and his team have developed RNAi technology to fight against respiratory tract viruses during the outbreak of SARS, H1N1 and its further development can work towards Coronavirus.

报告2:预防新冠肺炎的疫苗研发和防疫的中长期规划

报告人:巢守柏 博士

A person wearing a suit and tieDescription automatically generated

Shoubai Chao, PhD, COO of CanSino Biologics Inc., the 20th President of CBA. Dr. Chao and his team have been working on the recombinant Ebola vaccine that has been approved in China. Now he is focusing on the vaccine for SARS-CoV-2.

点评嘉宾:陆杭 博士

A person wearing a suit and tie smiling at the cameraDescription automatically generated

Dr. Hang Lu is CBA VP of Science Project and the director of BioAssay at Emergent BioSolutions and has been working in vaccine development at Emergent BioSolutions and Merck for ~ 20 years.  He has contributed to the development of several traditional and new generation vaccines from the preclinical to post approval in USA.

请关注下一讲:关于Remdesivir的临床研究  (3月4日8:30 pm of Eastern Time)